HS-20093 Generates Responses in Pretreated ES-SCLC - OncLive
HS-20093, a B7-H3–targeted ADC, showed promising efficacy in ES-SCLC patients with ORR of 61.3% at 8 mg/kg and 50.0% at 10 mg/kg in the ARTEMIS-001 trial. The 8 mg/kg dose had a better safety profile with no new safety signals identified. B7-H3 expression had a low correlation with tumor response.
Related Clinical Trials
Reference News
HS-20093 Generates Responses in Pretreated ES-SCLC - OncLive
HS-20093, a B7-H3–targeted ADC, showed promising efficacy in ES-SCLC patients with ORR of 61.3% at 8 mg/kg and 50.0% at 10 mg/kg in the ARTEMIS-001 trial. The 8 mg/kg dose had a better safety profile with no new safety signals identified. B7-H3 expression had a low correlation with tumor response.